Publications
Selected publications
- A Randomized Trial of Genotype-Guided Dosing of Warfarin (Journal article - 2013)
- STrengthening the Reporting Of Pharmacogenetic Studies: Development of the STROPS guideline (Journal article - 2020)
- Biomarker-guided trials: Challenges in practice (Journal article - 2019)
- Evidence to Support Inclusion of Pharmacogenetic Biomarkers in Randomised Controlled Trials (Journal article - 2019)
- Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study (Journal article - 2019)
- NAT2 variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis (Journal article - 2019)
- Association of variants within the <i>GST</i> and other genes with anti-tubercular agents related toxicity: a systematic review and meta-analysis (Journal article - 2019)
- <i>CYP</i> genetic variants and toxicity related to anti-tubercular agents: a systematic review and meta-analysis (Journal article - 2018)
- A genome-wide association study of stable warfarin dose in sub-Saharan African patients (Conference Paper - 2023)
- Susceptibility to corticosteroid-induced adrenal suppression: a genome-wide association study (Journal article - 2018)
2024
Benchmarking UMI-aware and standard variant callers for low frequency ctDNA variant detection.
Maruzani, R., Brierley, L., Jorgensen, A., & Fowler, A. (2024). Benchmarking UMI-aware and standard variant callers for low frequency ctDNA variant detection.. BMC genomics, 25(1), 827. doi:10.1186/s12864-024-10737-w
Meta-analysis of genome-wide association studies of stable warfarin dose in patients of African ancestry.
Asiimwe, I. G., Blockman, M., Cavallari, L. H., Cohen, K., Cupido, C. S., Dandara, C., . . . Pirmohamed, M. (2024). Meta-analysis of genome-wide association studies of stable warfarin dose in patients of African ancestry.. Blood advances, bloodadvances.2024014227. doi:10.1182/bloodadvances.2024014227
Long-term cisplatin nephrotoxicity after childhood cancer: a systematic review and meta-analysis
Schofield, J., Harcus, M., Pizer, B., Jorgensen, A., & McWilliam, S. (n.d.). Long-term cisplatin nephrotoxicity after childhood cancer: a systematic review and meta-analysis. Pediatric Nephrology. doi:10.1007/s00467-023-06149-9
Genetic Determinants of Thiazide-Induced Hyperuricemia, Hyperglycemia, and Urinary Electrolyte Disturbances - A Genome-Wide Evaluation of the UK Biobank.
Asiimwe, I. G., Walker, L., Sofat, R., Jorgensen, A. L., Pirmohamed, M., & Multimorbidity Mechanism and Therapeutic Research Collaborative (MMTRC). (2024). Genetic Determinants of Thiazide-Induced Hyperuricemia, Hyperglycemia, and Urinary Electrolyte Disturbances - A Genome-Wide Evaluation of the UK Biobank.. Clinical pharmacology and therapeutics. doi:10.1002/cpt.3229
Role of Transporters and Enzymes in Metabolism and Distribution of 4-Chlorokynurenine (AV-101).
Patel, W., Shankar, R. G., Smith, M. A., Snodgrass, H. R., Pirmohamed, M., Jorgensen, A. L., . . . Dickens, D. (2024). Role of Transporters and Enzymes in Metabolism and Distribution of 4-Chlorokynurenine (AV-101).. Molecular pharmaceutics. doi:10.1021/acs.molpharmaceut.3c00700
2023
Role of fatty liver index in risk-stratifying comorbid disease outcomes in non-alcoholic fatty liver disease.
Ho, B., Thompson, A., Jorgensen, A. L., & Pirmohamed, M. (2023). Role of fatty liver index in risk-stratifying comorbid disease outcomes in non-alcoholic fatty liver disease.. JHEP reports : innovation in hepatology, 5(12), 100896. doi:10.1016/j.jhepr.2023.100896
Benchmarking UMI-aware and standard variant callers on synthetic and real ctDNA datasets
Testing for pharmacogenomic predictors of ppRNFL thinning in individuals exposed to vigabatrin
Boothman, I., Clayton, L. M., Mccormack, M., Driscoll, A. M., Stevelink, R., Moloney, P., . . . Cavalleri, G. L. (2023). Testing for pharmacogenomic predictors of ppRNFL thinning in individuals exposed to vigabatrin. FRONTIERS IN NEUROSCIENCE, 17. doi:10.3389/fnins.2023.1156362
A "Bundle of Care" to Improve Anticoagulation Control in Patients Receiving Warfarin in Uganda and South Africa: Protocol for an Implementation Study
Jorgensen, A. L., Orrell, C., Waitt, C., Toh, C. -H., Sekaggya-Wiltshire, C., Hughes, D. A., . . . Pirmohamed, M. (2023). A "Bundle of Care" to Improve Anticoagulation Control in Patients Receiving Warfarin in Uganda and South Africa: Protocol for an Implementation Study. JMIR RESEARCH PROTOCOLS, 12. doi:10.2196/46710
A “Bundle of Care” to Improve Anticoagulation Control in Patients Receiving Warfarin in Uganda and South Africa: Protocol for an Implementation Study (Preprint)
Genome-wide analyses of platinum-induced ototoxicity in childhood cancer patients: Results of GO-CAT and United Kingdom MAGIC consortia.
Hurkmans, E. G. E., Klumpers, M. J., Dello Russo, C., De Witte, W., Guchelaar, H. -J., Gelderblom, H., . . . Te Loo, D. M. W. M. (2023). Genome-wide analyses of platinum-induced ototoxicity in childhood cancer patients: Results of GO-CAT and United Kingdom MAGIC consortia.. Frontiers in pharmacology, 13, 980309. doi:10.3389/fphar.2022.980309
<i>CYP3A</i> genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene study
McEvoy, L., Cliff, J., Carr, D. F., Jorgensen, A., Lord, R., & Pirmohamed, M. (2023). <i>CYP3A</i> genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene study. FRONTIERS IN PHARMACOLOGY, 14. doi:10.3389/fphar.2023.1178421
<i>CYP3A</i> genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene study (vol 14, 1178421, 2023)
Mcevoy, L., Cliff, J., Carr, D. F., Jorgensen, A., Lord, R., & Pirmohamed, M. (2023). <i>CYP3A</i> genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene study (vol 14, 1178421, 2023). FRONTIERS IN PHARMACOLOGY, 14. doi:10.3389/fphar.2023.1274075
A genome-wide association study of plasma concentrations of warfarin enantiomers and metabolites in sub-Saharan Black-African patients
Asiimwe, I., Zhang, E., Jorgensen, A., & Pirmohamed, M. (2023). A genome-wide association study of plasma concentrations of warfarin enantiomers and metabolites in sub-Saharan Black-African patients. In BRITISH JOURNAL OF CLINICAL PHARMACOLOGY Vol. 89 (pp. 1248-1249). Retrieved from https://www.webofscience.com/
A genome-wide association study of stable warfarin dose in sub-Saharan African patients
Asiimwe, I., Zhang, E., Jorgensen, A., & Pirmohamed, M. (2023). A genome-wide association study of stable warfarin dose in sub-Saharan African patients. In BRITISH JOURNAL OF CLINICAL PHARMACOLOGY Vol. 89 (pp. 1249). Retrieved from https://www.webofscience.com/
Blood group as a clinical risk factor in peptic ulcer disease: UK biobank analysis
McEvoy, L., Pirmohamed, M., Carr, D., & Jorgensen, A. (2023). Blood group as a clinical risk factor in peptic ulcer disease: UK biobank analysis. In BRITISH JOURNAL OF CLINICAL PHARMACOLOGY Vol. 89 (pp. 1243). Retrieved from https://www.webofscience.com/
Clinical Risk Factors in Peptic Ulcer Disease: UK Biobank Analysis
McEvoy, L., Pirmohamed, M., Carr, D., & Jorgensen, A. (2023). Clinical Risk Factors in Peptic Ulcer Disease: UK Biobank Analysis. In BRITISH JOURNAL OF PHARMACOLOGY Vol. 180 (pp. 276). Retrieved from https://www.webofscience.com/
Developing a warfarin dosing algorithm in patients with mechanical heart valves
Zhang, E., Stewart, A., Jorgensen, A., McEvoy, L., Carracedo, A. D., Foster, T., . . . Pirmohamed, M. (2023). Developing a warfarin dosing algorithm in patients with mechanical heart valves. In BRITISH JOURNAL OF CLINICAL PHARMACOLOGY Vol. 89 (pp. 1249-1250). Retrieved from https://www.webofscience.com/
Identifying and visualising multimorbidity and comorbidity patterns in patients in the English National Health Service: a population-based study
Kuan, V., Denaxas, S., Patalay, P., Nitsch, D., Mathur, R., Gonzalez-Izquierdo, A., . . . MMTRC. (2023). Identifying and visualising multimorbidity and comorbidity patterns in patients in the English National Health Service: a population-based study. LANCET DIGITAL HEALTH, 5(1), E16-E27. doi:10.1016/S2589-7500(22)00187-X
2022
Factors Associated With Diabetic Ketoacidosis at Onset of Type 1 Diabetes Among Pediatric Patients A Systematic Review
Rugg-Gunn, C. E. M., Dixon, E., Jorgensen, A. L., Usher-Smith, J. A., Marcovecchio, M. L., Deakin, M., & Hawcutt, D. B. (2022). Factors Associated With Diabetic Ketoacidosis at Onset of Type 1 Diabetes Among Pediatric Patients A Systematic Review. JAMA PEDIATRICS, 176(12), 1248-1259. doi:10.1001/jamapediatrics.2022.3586
Genetic Association Analysis of Epilepsy Prognosis Using Whole Exome Sequencing
Shankar, R. G., Morris, A. P., Sills, G., Marson, T., & Jorgensen, A. (2022). Genetic Association Analysis of Epilepsy Prognosis Using Whole Exome Sequencing. In GENETIC EPIDEMIOLOGY Vol. 46 (pp. 530-531). Retrieved from https://www.webofscience.com/
A genome-wide association study of plasma concentrations of warfarin enantiomers and metabolites in sub-Saharan black-African patients.
Asiimwe, I. G., Blockman, M., Cohen, K., Cupido, C., Hutchinson, C., Jacobson, B., . . . Pirmohamed, M. (2022). A genome-wide association study of plasma concentrations of warfarin enantiomers and metabolites in sub-Saharan black-African patients.. Frontiers in pharmacology, 13, 967082. doi:10.3389/fphar.2022.967082
Multi-ancestral meta-analysis yields novel genetic loci for asthma exacerbations
Herrera Luis, E., Ortega, V. E., Ampleford, E. J., Sio, Y. Y., Granell, R., De Roos, E., . . . Pino-Yanes, M. (2022). Multi-ancestral meta-analysis yields novel genetic loci for asthma exacerbations. In EUROPEAN RESPIRATORY JOURNAL Vol. 60. doi:10.1183/13993003.congress-2022.685
A review of software tools for statistical tests of genetic association with rare variants using next generation sequence data
Attainment of low disease activity and remission targets reduces the risk of severe flare and new damage in childhood lupus
Smith, E. M. D., Tharmaratnam, K., Al-Abadi, E., Armon, K., Bailey, K., Brennan, M., . . . Beresford, M. W. (n.d.). Attainment of low disease activity and remission targets reduces the risk of severe flare and new damage in childhood lupus. Rheumatology. doi:10.1093/rheumatology/keab915
459 Nephrotoxin-associated AKI in non-critically ill children: A single centre prospective audit
Hankinson, C., Oni, L., Jorgensen, A., & McWilliam, S. (2022). 459 Nephrotoxin-associated AKI in non-critically ill children: A single centre prospective audit. In British Association for Community Child Health (pp. A92.3-A93). BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health. doi:10.1136/archdischild-2022-rcpch.150
Cardiovascular drugs and COVID-19 clinical outcomes: a systematic review and meta-analysis of randomized controlled trials
Asiimwe, I. G., Pushpakom, S. P., Turner, R. M., Kolamunnage-Dona, R., Jorgensen, A. L., & Pirmohamed, M. (2022). Cardiovascular drugs and COVID-19 clinical outcomes: a systematic review and meta-analysis of randomized controlled trials. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 88(8), 3577-3599. doi:10.1111/bcp.15331
GENOME WIDE ANALYSIS IDENTIFIES POTENTIAL MECHANISMS OF NON-ALCOHOLIC FATTY LIVER DISEASE
Ho, B., Thompson, A., Jorgensen, A., & Pirmohamed, M. (2022). GENOME WIDE ANALYSIS IDENTIFIES POTENTIAL MECHANISMS OF NON-ALCOHOLIC FATTY LIVER DISEASE. In GUT Vol. 71 (pp. A14-A15). doi:10.1136/gutjnl-2022-BSG.25
Multi-ancestry genome-wide association study of asthma exacerbations
Herrera-Luis, E., Ortega, V. E., Ampleford, E. J., Sio, Y. Y., Granell, R., de Roos, E., . . . Pino-Yanes, M. (2022). Multi-ancestry genome-wide association study of asthma exacerbations. PEDIATRIC ALLERGY AND IMMUNOLOGY, 33(6). doi:10.1111/pai.13802
Real world treatment of juvenile-onset systemic lupus erythematosus: Data from the UK JSLE cohort study
Smith, E. M. D., Egbivwie, N., Jorgensen, A. L., Ciurtin, C., Al-Abadi, E., Armon, K., . . . Hedrich, C. M. (2022). Real world treatment of juvenile-onset systemic lupus erythematosus: Data from the UK JSLE cohort study. CLINICAL IMMUNOLOGY, 239. doi:10.1016/j.clim.2022.109028
978-3-319-52677-5
Jorgensen, A., Brown, L., Antoniou, M., & Wason, J. (2022). 978-3-319-52677-5. In S. Piantadosi, & C. Meinert (Eds.), Principles and practice of clinical trials. Springer.
A Systematic Review and Analysis of the Use of Polygenic Scores in Pharmacogenomics
Johnson, D., Wilke, M. A. P., Lyle, S. M., Kowalec, K., Jorgensen, A., Wright, G. E. B., & Drogemoller, B. I. (2022). A Systematic Review and Analysis of the Use of Polygenic Scores in Pharmacogenomics. CLINICAL PHARMACOLOGY & THERAPEUTICS, 111(4), 919-930. doi:10.1002/cpt.2520
Association of ultra-rare coding variants with genetic generalized epilepsy: A case-control whole exome sequencing study.
Koko, M., Motelow, J. E., Stanley, K. E., Bobbili, D. R., Dhindsa, R. S., May, P., . . . EuroEPINOMICS-CoGIE Consortium. (2022). Association of ultra-rare coding variants with genetic generalized epilepsy: A case-control whole exome sequencing study.. Epilepsia, 63(3), 723-735. doi:10.1111/epi.17166
Cardiovascular drugs and COVID-19 clinical outcomes: a systematic review and meta-analysis of randomized controlled trials
Asiimwe, I., Pushpakom, S., Turner, R., Kolamunnage-Dona, R., Jorgensen, A., & Pirmohamed, M. (2022). Cardiovascular drugs and COVID-19 clinical outcomes: a systematic review and meta-analysis of randomized controlled trials. doi:10.22541/au.164431813.39836023/v1
Vitamin D, vitamin D-binding protein, free vitamin D and COVID-19 mortality in hospitalized patients
Subramanian, S., Rhodes, J. M., Taylor, J. M., Milan, A. M., Lane, S., Hewison, M., . . . Pirmohamed, M. (2022). Vitamin D, vitamin D-binding protein, free vitamin D and COVID-19 mortality in hospitalized patients. AMERICAN JOURNAL OF CLINICAL NUTRITION. doi:10.1093/ajcn/nqac027
Biomarker-Guided Trials
Brown, L. C., Jorgensen, A. L., Antoniou, M., & Wason, J. (2022). Biomarker-Guided Trials. In Principles and Practice of Clinical Trials (pp. 1145-1170). Springer International Publishing. doi:10.1007/978-3-319-52636-2_168
Biomarker-Guided Trials
Brown, L. C., Jorgensen, A. L., Antoniou, M., & Wason, J. (2022). Biomarker-Guided Trials. In Principles and Practice of Clinical Trials (pp. 1-26). Springer International Publishing. doi:10.1007/978-3-319-52677-5_168-2
Polygenic risk score analysis reveals shared genetic burden between epilepsy and psychiatric comorbidities
Campbell, C., Lewis-Smith, D., Leu, C., Martins, H., Krause, R., O'Brien, T., . . . Cavalleri, G. L. (2022). Polygenic risk score analysis reveals shared genetic burden between epilepsy and psychiatric comorbidities. In EUROPEAN JOURNAL OF HUMAN GENETICS Vol. 30 (pp. 31-32). Retrieved from https://www.webofscience.com/
Selecting subsets of immune repertoire features improves prediction of coeliac disease status using machine learning
Kockelbergh, H., Shoukat, M. S., Evans, S. C., Brierley, L., Jorgensen, A. L., Green, P. L., . . . Fowler, A. (2022). Selecting subsets of immune repertoire features improves prediction of coeliac disease status using machine learning. In HUMAN HEREDITY Vol. VOL. (pp. 14-15). Retrieved from https://www.webofscience.com/
Stable warfarin dose prediction in sub-Saharan African patients: A machine-learning approach and external validation of a clinical dose-initiation algorithm
Asiimwe, I. G., Blockman, M., Cohen, K., Cupido, C., Hutchinson, C., Jacobson, B., . . . Pirmohamed, M. (2022). Stable warfarin dose prediction in sub-Saharan African patients: A machine-learning approach and external validation of a clinical dose-initiation algorithm. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 11(1), 20-29. doi:10.1002/psp4.12740
2021
rareSurvival: rare variant association analysis for “time-to-event” outcomes
Cardiovascular drugs and COVID-19 clinical outcomes: A living systematic review and meta-analysis
Asiimwe, I. G., Pushpakom, S., Turner, R. M., Kolamunnage-Dona, R., Jorgensen, A. L., & Pirmohamed, M. (2021). Cardiovascular drugs and COVID-19 clinical outcomes: A living systematic review and meta-analysis. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87(12), 4534-+. doi:10.1111/bcp.14927
Genome-Wide association between EYA1 and Aspirin-induced peptic ulceration
Bourgeois, S., Carr, D. F., Musumba, C. O., Penrose, A., Esume, C., Morris, A. P., . . . Pirmohamed, M. (2021). Genome-Wide association between EYA1 and Aspirin-induced peptic ulceration. EBioMedicine, 74, 103728. doi:10.1016/j.ebiom.2021.103728
High-mobility group box 1 as a predictive biomarker for drug-resistant epilepsy: A proof-of-concept study
Walker, L. E., Sills, G. J., Jorgensen, A., Alapirtti, T., Peltola, J., Brodie, M. J., . . . Pirmohamed, M. (2021). High-mobility group box 1 as a predictive biomarker for drug-resistant epilepsy: A proof-of-concept study. EPILEPSIA. doi:10.1111/epi.17116
Developing and Validating a Clinical Warfarin Dose-Initiation Model for Black-African Patients in South Africa and Uganda (vol 109, pg 1564, 2021)
Asiimwe, I. G., Waitt, C., Sekaggya-Wiltshire, C., Hutchinson, C., Okello, E., Zhang, E. J., . . . Pirmohamed, M. (2021). Developing and Validating a Clinical Warfarin Dose-Initiation Model for Black-African Patients in South Africa and Uganda (vol 109, pg 1564, 2021). CLINICAL PHARMACOLOGY & THERAPEUTICS, 110(5), 1402. doi:10.1002/cpt.2395
1136 Drug-induced acute kidney injury in non-critically ill, hospitalised children: a systematic review and meta-analysis
Hankinson, C., Oni, L., Jorgensen, A., & McWilliam, S. (2021). 1136 Drug-induced acute kidney injury in non-critically ill, hospitalised children: a systematic review and meta-analysis. In Abstracts (pp. A243.1-A243). BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health. doi:10.1136/archdischild-2021-rcpch.423
1675 Real world treatment of juvenile systemic lupus erythematosus (JSLE): evidence from the UK JSLE cohort study
Egbivwie, N., Jorgensen, A. L., Beresford, M. W., Hedrich, C. M., & Smith, E. M. D. (2021). 1675 Real world treatment of juvenile systemic lupus erythematosus (JSLE): evidence from the UK JSLE cohort study. In Abstracts (pp. A454). BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health. doi:10.1136/archdischild-2021-rcpch.790
Genome-wide association studies of exacerbations in children using long-acting beta2-agonists
Slob, E. M. A., Richards, L. B., Vijverberg, S. J. H., Longo, C., Koppelman, G. H., Pijnenburg, M. W. H., . . . Maitland-van der Zee, A. H. (2021). Genome-wide association studies of exacerbations in children using long-acting beta2-agonists. PEDIATRIC ALLERGY AND IMMUNOLOGY, 32(6), 1197-1207. doi:10.1111/pai.13494
Identification of ROBO2 as a Potential Locus Associated with Inhaled Corticosteroid Response in Childhood Asthma
Hernandez-Pacheco, N., Gorenjak, M., Li, J., Repnik, K., Vijverberg, S. J., Berce, V., . . . Pino-Yanes, M. (n.d.). Identification of ROBO2 as a Potential Locus Associated with Inhaled Corticosteroid Response in Childhood Asthma. Journal of Personalized Medicine, 11(8), 733. doi:10.3390/jpm11080733
ADRB2 Haplotypes and Asthma Exacerbations in Children and Young Adults: An Individual Participant Data Meta-Analysis.
Karimi, L., Vijverberg, S. J., Engelkes, M., Hernandez-Pacheco, N., Farzan, N., Soares, P., . . . PiCA, SysPharmPedia consortia. (2021). ADRB2 Haplotypes and Asthma Exacerbations in Children and Young Adults: An Individual Participant Data Meta-Analysis.. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. doi:10.1111/cea.13965
Assessing the role of rare genetic variants in drug-resistant, non-lesional focal epilepsy
Wolking, S., Moreau, C., McCormack, M., Krause, R., Krenn, M., Berkovic, S., . . . Cossette, P. (2021). Assessing the role of rare genetic variants in drug-resistant, non-lesional focal epilepsy. ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 8(7), 1376-1387. doi:10.1002/acn3.51374
Developing and Validating a Clinical Warfarin Dose-Initiation Model for Black-African Patients in South Africa and Uganda
Asiimwe, I. G., Waitt, C., Sekaggya-Wiltshire, C., Hutchinson, C., Okello, E., Zhang, E. J., . . . Pirmohamed, M. (2021). Developing and Validating a Clinical Warfarin Dose-Initiation Model for Black-African Patients in South Africa and Uganda. CLINICAL PHARMACOLOGY & THERAPEUTICS, 109(6), 1564-1574. doi:10.1002/cpt.2128
Combined analysis of transcriptomic and genetic data for the identification of loci involved in glucocorticosteroid response in asthma
Hernandez-Pacheco, N., Gorenjak, M., Jurgec, S., Corrales, A., Jorgensen, A., Karimi, L., . . . Pino-Yanes, M. (2021). Combined analysis of transcriptomic and genetic data for the identification of loci involved in glucocorticosteroid response in asthma. ALLERGY, 76(4), 1238-1243. doi:10.1111/all.14552
Warfarin dosing algorithms: A systematic review
Asiimwe, I. G., Zhang, E. J., Osanlou, R., Jorgensen, A. L., & Pirmohamed, M. (2021). Warfarin dosing algorithms: A systematic review. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87(4), 1717-1729. doi:10.1111/bcp.14608
Biomarker-Guided Trials
Brown, L. C., Jorgensen, A. L., Antoniou, M., & Wason, J. (2021). Biomarker-Guided Trials. In Principles and Practice of Clinical Trials (pp. 1-26). Springer International Publishing. doi:10.1007/978-3-319-52677-5_168-1
Clinical and pharmacogenetic determinants of tenofovir-induced renal toxicity in HIV positive patients in Zambia
Hamachila, A., Pushpakom, S., Jorgensen, A., & Pirmohamed, M. (2021). Clinical and pharmacogenetic determinants of tenofovir-induced renal toxicity in HIV positive patients in Zambia. In BRITISH JOURNAL OF CLINICAL PHARMACOLOGY Vol. 87 (pp. 4889). Retrieved from https://www.webofscience.com/
Meta-Analysis of Genome-Wide Association Studies of Exacerbations in Children Using Long-Acting Beta-Agonists
Slob, E., Richards, L. B., Vijverberg, S., Longo, C., Koppelman, G. H., Pijnenburg, M. W., . . . Maitland-van der Zee, A. H. (2021). Meta-Analysis of Genome-Wide Association Studies of Exacerbations in Children Using Long-Acting Beta-Agonists. In AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE Vol. 203. Retrieved from https://www.webofscience.com/
2020
Cardiovascular drugs and COVID-19 clinical outcomes: a living systematic review and meta-analysis
Asiimwe, I., Pushpakom, S., Turner, R., Kolamunnage-Dona, R., Jorgensen, A., & Pirmohamed, M. (2020). Cardiovascular drugs and COVID-19 clinical outcomes: a living systematic review and meta-analysis. doi:10.1101/2020.10.07.20208918
STrengthening the Reporting Of Pharmacogenetic Studies: Development of the STROPS guideline
Chaplin, M., Kirkham, J. J., Dwan, K., Sloan, D. J., Davies, G., & Jorgensen, A. L. (2020). STrengthening the Reporting Of Pharmacogenetic Studies: Development of the STROPS guideline. PLOS MEDICINE, 17(9). doi:10.1371/journal.pmed.1003344
Antiepileptic Drug Teratogenicity and De Novo Genetic Variation Load.
Perucca, P., Anderson, A., Jazayeri, D., Hitchcock, A., Graham, J., Todaro, M., . . . EpiPGX and EPIGEN Consortia. (2020). Antiepileptic Drug Teratogenicity and De Novo Genetic Variation Load.. Annals of neurology, 87(6), 897-906. doi:10.1002/ana.25724
Genetic factors influencing warfarin dose in Black-African patients: a systematic review and meta-analysis.
Asiimwe, I. G., Zhang, E. J., Osanlou, R., Krause, A., Dillon, C., Suarez-Kurtz, G., . . . Pirmohamed, M. (2020). Genetic factors influencing warfarin dose in Black-African patients: a systematic review and meta-analysis.. Clinical Pharmacology and Therapeutics, 107(6), 1420-1433. doi:10.1002/cpt.1755
Testing association of rare genetic variants with resistance to three common antiseizure medications
Wolking, S., Moreau, C., Nies, A. T., Schaeffeler, E., McCormack, M., Auce, P., . . . Lerche, H. (2020). Testing association of rare genetic variants with resistance to three common antiseizure medications. EPILEPSIA, 61(4), 657-666. doi:10.1111/epi.16467
A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa
Semakula, J. R., Mouton, J. P., Jorgensen, A., Hutchinson, C., Allie, S., Semakula, L., . . . Cohen, K. (2020). A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. PLOS ONE, 15(1). doi:10.1371/journal.pone.0227458
Whole exome sequencing analysis of complex "Time-To-Event" outcomes in epilepsy patients
Shankar, R. G., Morris, A. P., Sills, G., Marson, T., & Jorgensen, A. (2020). Whole exome sequencing analysis of complex "Time-To-Event" outcomes in epilepsy patients. In GENETIC EPIDEMIOLOGY Vol. 44 (pp. 484). Retrieved from https://www.webofscience.com/
2019
Exploring the potential of BH3 mimetic therapy in squamous cell carcinoma of the head and neck
Carter, R. J., Milani, M., Butterworth, M., Alotibi, A., Harper, N., Yedida, G., . . . Varadarajan, S. (2019). Exploring the potential of BH3 mimetic therapy in squamous cell carcinoma of the head and neck. Cell Death and Disease, 10(12). doi:10.1038/s41419-019-2150-8
Biomarker-guided trials: Challenges in practice
Antoniou, M., Kolamunnage-Dona, R., Wason, J., Bathia, R., Billingham, C., Bliss, J. M., . . . Jorgensen, A. L. (2019). Biomarker-guided trials: Challenges in practice. Contemporary Clinical Trials Communications, 16, 100493. doi:10.1016/j.conctc.2019.100493
Genomewide Association Study of Statin‐Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink
Carr, D. (2019). Genomewide Association Study of Statin‐Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink. Clinical Pharmacology and Therapeutics, 106(6), 1353-1361. doi:10.1002/cpt.1557
Susceptibility to corticosteroid-induced adrenal suppression: a genome-wide association study
DB, H., B, F., DF, C., AL, J., P, Y., N, W., . . . M, P. (n.d.). Susceptibility to corticosteroid-induced adrenal suppression: a genome-wide association study. Yearbook of Paediatric Endocrinology. doi:10.1530/ey.16.8.11
Comparative effectiveness of antiepileptic drugs in juvenile myoclonic epilepsy
Silvennoinen, K., de Lange, N., Zagaglia, S., Balestrini, S., Androsova, G., Wassenaar, M., . . . Sisodiya, S. M. (2019). Comparative effectiveness of antiepileptic drugs in juvenile myoclonic epilepsy. EPILEPSIA OPEN, 4(3), 420-430. doi:10.1002/epi4.12349
Evidence to Support Inclusion of Pharmacogenetic Biomarkers in Randomised Controlled Trials
Johnson, D., Hughes, D., Pirmohamed, M., & Jorgensen, A. (2019). Evidence to Support Inclusion of Pharmacogenetic Biomarkers in Randomised Controlled Trials. JOURNAL OF PERSONALIZED MEDICINE, 9(3). doi:10.3390/jpm9030042
Genetic testing for prevention of severe drug-induced skin rash.
Alfirevic, A., Pirmohamed, M., Marinovic, B., Harcourt-Smith, L., Jorgensen, A. L., & Cooper, T. E. (2019). Genetic testing for prevention of severe drug-induced skin rash.. The Cochrane Database of Systematic Reviews, 7, CD010891. doi:10.1002/14651858.cd010891.pub2
Protocol for the development of the STrengthening the Reporting Of Pharmacogenetic Studies (STROPS) guideline: checklist of items for reporting pharmacogenetic studies
Richardson, M., Kirkham, J. J., Dwan, K. M., Sloan, D. J., Davies, G., & Jorgensen, A. (2019). Protocol for the development of the STrengthening the Reporting Of Pharmacogenetic Studies (STROPS) guideline: checklist of items for reporting pharmacogenetic studies. BMJ OPEN, 9(7). doi:10.1136/bmjopen-2019-030212
HMGB1 expression in SJS/TEN sera and skin
Carr, D. F., Wang, C., Bellón, T., Ressel, L., Nwikue, G., Shrivastava, V., . . . Pirmohamed, M. (2019). HMGB1 expression in SJS/TEN sera and skin. British Journal of Dermatology, 181(1). doi:10.1111/bjd.18061
Serum and blister-fluid elevation and decreased epidermal content of high-mobility group box 1 protein in drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis
Carr, D. F., Wang, C. -W., Bellon, T., Ressel, L., Nwikue, G., Shrivastava, V., . . . Pirmohamed, M. (2019). Serum and blister-fluid elevation and decreased epidermal content of high-mobility group box 1 protein in drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. BRITISH JOURNAL OF DERMATOLOGY, 181(1), 166-174. doi:10.1111/bjd.17610
药物引发的史蒂文斯‐约翰逊综合征/中毒性表皮坏死松解症患者血清及水泡液中高迁移率族蛋白 B 的蛋白含量高迁移率族
Carr, D. F., Wang, C., Bellón, T., Ressel, L., Nwikue, G., Shrivastava, V., . . . Pirmohamed, M. (2019). 药物引发的史蒂文斯‐约翰逊综合征/中毒性表皮坏死松解症患者血清及水泡液中高迁移率族蛋白 B 的蛋白含量高迁移率族. British Journal of Dermatology, 181(1). doi:10.1111/bjd.18080
Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study
Jorgensen, A. L., Prince, C., Fitzgerald, G., Hanson, A., Downing, J., Reynolds, J., . . . Pirmohamed, M. (2019). Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study. BMC Medicine, 17. doi:10.1186/s12916-019-1308-7
Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy (Retraction of Vol 127, Pg 2118, 2017)
Walker, L. E., Frigerio, F., Ravizza, T., Ricci, E., Tse, K., Jenkins, R. E., . . . Pirmohamed, M. (2019). Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy (Retraction of Vol 127, Pg 2118, 2017). JOURNAL OF CLINICAL INVESTIGATION, 129(5), 2166. doi:10.1172/JCI129285
A genome-wide association study of sodium levels and drug metabolism in an epilepsy cohort treated with carbamazepine and oxcarbazepine.
Berghuis, B., Stapleton, C., Sonsma, A. C. M., Hulst, J., de Haan, G. -J., Lindhout, D., . . . McCormack, M. (2019). A genome-wide association study of sodium levels and drug metabolism in an epilepsy cohort treated with carbamazepine and oxcarbazepine.. Epilepsia Open, 4(1), 102-109. doi:10.1002/epi4.12297
NAT2 variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis
Richardson, M., Kirkham, J., Dwan, K., Sloan, D. J., Davies, G., & Jorgensen, A. L. (2019). NAT2 variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 23(3), 293-305. doi:10.5588/ijtld.18.0324
Association of variants within the <i>GST</i> and other genes with anti-tubercular agents related toxicity: a systematic review and meta-analysis
Richardson, M., Kirkham, J., Dwan, K., Sloan, D., Davies, G., & Jorgensen, A. (2019). Association of variants within the <i>GST</i> and other genes with anti-tubercular agents related toxicity: a systematic review and meta-analysis. doi:10.1101/515817
A discrete choice experiment to measure public preferences for genetic testing to prevent adverse drug reactions
Johnson, D., Jorgensen, A., Hughes, D., & Pirmohamed, S. M. (2019). A discrete choice experiment to measure public preferences for genetic testing to prevent adverse drug reactions. In TRIALS Vol. 20. Retrieved from https://www.webofscience.com/
2018
Growing international evidence for urinary biomarker panels identifying lupus nephritis in children - verification within the South African Paediatric Lupus Cohort
Smith, E. M. D., Lewandowski, L. B., Jorgensen, A. L., Phuti, A., Nourse, P., Scott, C., & Beresford, M. W. (2018). Growing international evidence for urinary biomarker panels identifying lupus nephritis in children - verification within the South African Paediatric Lupus Cohort. LUPUS, 27(14), 2190-2199. doi:10.1177/0961203318808376
<i>CYP</i> genetic variants and toxicity related to anti-tubercular agents: a systematic review and meta-analysis
Richardson, M., Kirkham, J., Dwan, K., Sloan, D. J., Davies, G., & Jorgensen, A. L. (2018). <i>CYP</i> genetic variants and toxicity related to anti-tubercular agents: a systematic review and meta-analysis. SYSTEMATIC REVIEWS, 7. doi:10.1186/s13643-018-0861-z
Clinical predictors of active LN development in children - evidence from the UK JSLE Cohort Study
Smith, E. M. D., Yin, P., Jorgensen, A. L., & Beresford, M. W. (2018). Clinical predictors of active LN development in children - evidence from the UK JSLE Cohort Study. LUPUS, 27(13), 2020-2028. doi:10.1177/0961203318801526
A comparison of joint models for longitudinal and competing risks data, with application to an epilepsy drug randomized controlled trial
Hickey, G., Philipson, P., Jorgensen, A., & Kolamunnage-Dona, R. (2018). A comparison of joint models for longitudinal and competing risks data, with application to an epilepsy drug randomized controlled trial. Journal of the Royal Statistical Society Series A: Statistics in Society, 181(04), 1105-1123. doi:10.1111/rssa.12348
Susceptibility to corticosteroid-induced adrenal suppression: a genome-wide association study
DB, H., B, F., DF, C., AL, J., P, Y., N, W., . . . M, P. (n.d.). Susceptibility to corticosteroid-induced adrenal suppression: a genome-wide association study. Yearbook of Paediatric Endocrinology. doi:10.1530/ey.15.8.6
Rare coding variants in genes encoding GABA<sub>A</sub> receptors in genetic generalised epilepsies: an exome-based case-control study
May, P., Girard, S., Harrer, M., Bobbili, D. R., Schubert, J., Wolking, S., . . . Lerche, H. (2018). Rare coding variants in genes encoding GABA<sub>A</sub> receptors in genetic generalised epilepsies: an exome-based case-control study. LANCET NEUROLOGY, 17(8), 699-708. doi:10.1016/S1474-4422(18)30215-1
joineRML: a joint model and software package for time-to-event and multivariate longitudinal outcomes
Hickey, G. L., Philipson, P., Jorgensen, A., & Kolamunnage-Dona, R. (2018). joineRML: a joint model and software package for time-to-event and multivariate longitudinal outcomes. BMC MEDICAL RESEARCH METHODOLOGY, 18. doi:10.1186/s12874-018-0502-1
PO-027 Potential use of BH3 mimetics in the treatment of head and neck cancer
Carter, R. J., Butterworth, M., Risk, J. M., Jorgensen, A. L., Sacco, J. J., Schache, A. G., . . . Varadarajan, S. (2018). PO-027 Potential use of BH3 mimetics in the treatment of head and neck cancer. In ESMO Open Vol. 3 (pp. A238). Elsevier BV. doi:10.1136/esmoopen-2018-eacr25.562
Susceptibility to corticosteroid-induced adrenal suppression: a genome-wide association study
Hawcutt, D. B., Francis, B., Carr, D., Jorgensen, A. L., Yin, P., Wallin, N., . . . Pirmohamed, M. (2018). Susceptibility to corticosteroid-induced adrenal suppression: a genome-wide association study. The Lancet Respiratory Medicine, 6(6), 442-450. doi:10.1016/S2213-2600(18)30058-4
Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review (vol 7, 1, 2017)
Antoniou, M., Kolamunnage-Dona, R., & Jorgensen, A. L. (2018). Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review (vol 7, 1, 2017). JOURNAL OF PERSONALIZED MEDICINE, 8(2). doi:10.3390/jpm8020017
Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size (vol 7, 19, 2017)
Antoniou, M., Jorgensen, A. L., & Kolamunnage-Dona, R. (2018). Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size (vol 7, 19, 2017). JOURNAL OF PERSONALIZED MEDICINE, 8(2). doi:10.3390/jpm8020018
WITHDRAWN: Reference intervals for putative biomarkers of drug-induced liver injury and liver regeneration in healthy human volunteers.
Francis, B., Clarke, J. I., Walker, L. E., Brillant, N., Jorgensen, A. L., Park, B. K., . . . Antoine, D. J. (2018). WITHDRAWN: Reference intervals for putative biomarkers of drug-induced liver injury and liver regeneration in healthy human volunteers.. Journal of hepatology, S0168-8278(18)32042-7. doi:10.1016/j.jhep.2018.04.024
Urinary Biomarkers of Aminoglycoside-Induced Nephrotoxicity in Cystic Fibrosis: Kidney Injury Molecule-1 and Neutrophil Gelatinase-Associated Lipocalin
McWilliam, S. J., Antoine, D. J., Jorgensen, A. L., Smyth, R. L., & Pirmohamed, M. (2018). Urinary Biomarkers of Aminoglycoside-Induced Nephrotoxicity in Cystic Fibrosis: Kidney Injury Molecule-1 and Neutrophil Gelatinase-Associated Lipocalin. Scientific Reports, 8. doi:10.1038/s41598-018-23466-4
Clinical predictors of proteinuric remission following an LN flare - evidence from the UK JSLE cohort study
Smith, E. M. D., Yin, P., Jorgensen, A., & Beresford, M. (2018). Clinical predictors of proteinuric remission following an LN flare - evidence from the UK JSLE cohort study. Pediatric Rheumatology Online Journal, 16(1). doi:10.1186/s12969-018-0230-4
Aspirin non-responsiveness in pregnant women at high-risk of pre-eclampsia
Navaratnam, K., Alfirevic, A., Jorgensen, A., & Alfirevic, Z. (2018). Aspirin non-responsiveness in pregnant women at high-risk of pre-eclampsia. EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 221, 144-150. doi:10.1016/j.ejogrb.2017.12.052
Risk stratification after paracetamol overdose using mechanistic biomarkers: results from two prospective cohort studies
Dear, J. W., Clarke, J. I., Francis, B., Allen, L., Wraight, J., Shen, J., . . . Antoine, D. J. (2018). Risk stratification after paracetamol overdose using mechanistic biomarkers: results from two prospective cohort studies. The Lancet Gastroenterology and Hepatology, 3(2), 104-113. doi:10.1016/S2468-1253(17)30266-2
Joint models of longitudinal and time-to-event data with more than one event time outcome: a review
Hickey, G. L., Philipson, P., Jorgensen, A., & Kolamunnage-Dona, R. (2018). Joint models of longitudinal and time-to-event data with more than one event time outcome: a review. The International Journal of Biostatistics, 14(1). doi:10.1515/ijb-2017-0047
Development of reporting guidelines for pharmacogenetic studies to facilitate evidence synthesis
Richardson, M., Kirkham, J., Dwan, K., Sloan, D., Davies, G., & Jorgensen, A. (2018). Development of reporting guidelines for pharmacogenetic studies to facilitate evidence synthesis. In GENETIC EPIDEMIOLOGY Vol. 42 (pp. 727). Retrieved from https://www.webofscience.com/
2017
Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size
Antoniou, M., Jorgensen, A. L., & Kolamunnage-Dona, R. (2017). Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size. JOURNAL OF PERSONALIZED MEDICINE, 7(4). doi:10.3390/jpm7040019
GWAS FOR EARLY REMISSION IN NEWLY DIAGNOSED FOCAL EPILEPSY
Auce, P., Francis, B., Langley, S. R., Jorgensen, A., Marson, A. G., & Sills, G. J. (2017). GWAS FOR EARLY REMISSION IN NEWLY DIAGNOSED FOCAL EPILEPSY. In JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY Vol. 88 (pp. A22). doi:10.1136/jnnp-2017-ABN.73
The molecular genetics of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis
Cliff, J., Jorgensen, A. L., Lord, R., Azam, F., Cossar, L., Carr, D. F., & Pirmohamed, M. (2017). The molecular genetics of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 120, 127-140. doi:10.1016/j.critrevonc.2017.09.009
Do classic blood biomarkers of JSLE identify active lupus nephritis? Evidence from the UK JSLE Cohort Study.
Smith, E. M. D., Jorgensen, A. L., & Beresford, M. W. (2017). Do classic blood biomarkers of JSLE identify active lupus nephritis? Evidence from the UK JSLE Cohort Study.. Lupus, 26(11), 1212-1217. doi:10.1177/0961203317702253
Overview of Systematic Reviews of Therapeutic Ranges: Establishing the Threshold of Increased Drug Toxicity
Moss, J., Cooney, L., Golder, S., Loke, Y., Jorgensen, A., Sinha, I., & Hawcutt, D. (2017). Overview of Systematic Reviews of Therapeutic Ranges: Establishing the Threshold of Increased Drug Toxicity. In DRUG SAFETY Vol. 40 (pp. 985). Retrieved from https://www.webofscience.com/
Evaluation of agreement of placental growth factor (PlGF) tests and the soluble FMS-like tyrosine kinase 1 (sFlt - 1)/PlGF ratio, comparison of predictive accuracy for preeclampsia, and relation to uterine artery Doppler and response to aspirin
Navaratnam, K., Abreu, P., Clarke, H., Jorgensen, A., Alfirevic, A., & Alfirevic, Z. (2017). Evaluation of agreement of placental growth factor (PlGF) tests and the soluble FMS-like tyrosine kinase 1 (sFlt - 1)/PlGF ratio, comparison of predictive accuracy for preeclampsia, and relation to uterine artery Doppler and response to aspirin. The Journal of Maternal-Fetal and Neonatal Medicine, 32(2), 179-187. doi:10.1080/14767058.2017.1373760
Influence of genetic variants on toxicity to anti-tubercular agents: a systematic review and meta-analysis (protocol)
Richardson, M. H., Kirkham, J., Dwan, K., Sloan, D., Davies, G., & Jorgensen, A. (2017). Influence of genetic variants on toxicity to anti-tubercular agents: a systematic review and meta-analysis (protocol). Systematic Reviews. doi:10.1186/s13643-017-0533-4
Carbamazepine- and oxcarbazepine-induced hyponatremia in people with epilepsy
Berghuis, B., van der Palen, J., de Haan, G. -J., Lindhout, D., Koeleman, B. P. C., & Sander, J. W. (2017). Carbamazepine- and oxcarbazepine-induced hyponatremia in people with epilepsy. EPILEPSIA, 58(7), 1227-1233. doi:10.1111/epi.13777
Mechanistic biomarkers stratify patients after paracetamol overdose with high sensitivity and specificity
Dear, J. W., Clarke, J. I., Francis, B., Philips, L., Wraight, J., Dargan, P. I., . . . Antoine, D. J. (2017). Mechanistic biomarkers stratify patients after paracetamol overdose with high sensitivity and specificity. In CLINICAL TOXICOLOGY Vol. 55 (pp. 468). Retrieved from https://www.webofscience.com/
Overview of systematic reviews of therapeutic ranges: methodologies and recommendations for practice.
Cooney, L., Loke, Y. K., Golder, S., Kirkham, J., Jorgensen, A., Sinha, I., & Hawcutt, D. (2017). Overview of systematic reviews of therapeutic ranges: methodologies and recommendations for practice.. BMC medical research methodology, 17(1). doi:10.1186/s12874-017-0363-z
Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy
Ricci, E. (2017). Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy. Journal of Clinical Investigation, 127(6), 2118-2132. doi:10.1172/JCI92001
Effect of Genetic Variability in the <i>CYP4F2, CYP4F11</i>, and <i>CYP4F12</i> Genes on Liver mRNA Levels and Warfarin Response
Zhang, J. E., Klein, K., Jorgensen, A. L., Francis, B., Alfirevic, A., Bourgeois, S., . . . Pirmohamed, M. (2017). Effect of Genetic Variability in the <i>CYP4F2, CYP4F11</i>, and <i>CYP4F12</i> Genes on Liver mRNA Levels and Warfarin Response. FRONTIERS IN PHARMACOLOGY, 8. doi:10.3389/fphar.2017.00323
SurvivalGWAS_SV: software for the analysis of genome-wide association studies of imputed genotypes with "time-to-event" outcomes
Syed, H., Jorgensen, A. L., & Morris, A. P. (2017). SurvivalGWAS_SV: software for the analysis of genome-wide association studies of imputed genotypes with "time-to-event" outcomes. BMC bioinformatics, 18. doi:10.1186/s12859-017-1683-z
Biomarker-guided clinical trial designs: sample size calculations with survival endpoints
Antoniou, M., Kolamunnage-Dona, R., & Jorgensen, A. L. (2017). Biomarker-guided clinical trial designs: sample size calculations with survival endpoints. In TRIALS Vol. 18. Retrieved from https://www.webofscience.com/
Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part two
Lomakina, O., Alekseeva, E., Valieva, S., Bzarova, T., Nikishina, I., Zholobova, E., . . . Rose, C. (2017). Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part two. Pediatric Rheumatology, 15(S1). doi:10.1186/s12969-017-0142-8
International validation of a urinary biomarker panel for identification of active lupus nephritis in children.
Smith, E. M. D., Jorgensen, A. L., Midgley, A., Oni, L., Goilav, B., Putterman, C., . . . Beresford, M. W. (2017). International validation of a urinary biomarker panel for identification of active lupus nephritis in children.. Pediatric Nephrology, 32(2), 283-295. doi:10.1007/s00467-016-3485-3
Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review
Antoniou, M., Kolamunnage-Dona, R., & Jorgensen, A. L. (2017). Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. Journal of Personalized Medicine, 7(1). doi:10.3390/jpm7010001
<i>TPMT</i>, <i>COMT</i> and <i>ACYP2</i> genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity
Thiesen, S., Yin, P., Jorgensen, A. L., Zhang, J. E., Manzo, V., McEvoy, L., . . . Pirmohamed, M. (2017). <i>TPMT</i>, <i>COMT</i> and <i>ACYP2</i> genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity. PHARMACOGENETICS AND GENOMICS, 27(6), 213-222. doi:10.1097/FPC.0000000000000281
Development and Application of Methodology for the Analysis of Rare Genetic Variants with Time to Event Outcomes Using SurvivalGWAS_RV
Syed, H., Jorgensen, A. L., & Morris, A. P. (2017). Development and Application of Methodology for the Analysis of Rare Genetic Variants with Time to Event Outcomes Using SurvivalGWAS_RV. In GENETIC EPIDEMIOLOGY Vol. 41 (pp. 685-686). Retrieved from https://www.webofscience.com/
Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome
Turner, R. M., Yin, P., Hanson, A., FitzGerald, R., Morris, A. P., Stables, R. H., . . . Pirmohamed, M. (2017). Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome. Journal of Clinical Lipidology, 11(1), 204-214. doi:10.1016/j.jacl.2016.12.007
2016
A comparison of HMGB1 concentrations between cerebrospinal fluid and blood in patients with neurological disease
Walker, L., Griffiths, M. J., McGill, F., Lewthwaite, P., Sills, G. J., Jorgensen, A., . . . Pirmohamed, M. (2016). A comparison of HMGB1 concentrations between cerebrospinal fluid and blood in patients with neurological disease. Biomarkers, 22(7), 635-642. doi:10.1080/1354750X.2016.1265003
SurvivalGWAS_Power: a user friendly tool for power calculations in pharmacogenetic studies with "time to event" outcomes
Syed, H., Jorgensen, A. L., & Morris, A. P. (2016). SurvivalGWAS_Power: a user friendly tool for power calculations in pharmacogenetic studies with "time to event" outcomes. BMC BIOINFORMATICS, 17. doi:10.1186/s12859-016-1407-9
SNP-Treatment Interactions of Cardiovascular Medications and Risk of Acute Coronary Syndrome Recurrence
Yin, P., Jorgensen, A., Morris, A., Turner, R., Fitzgerald, R., Stables, R., . . . Pirmohamed, M. (2016). SNP-Treatment Interactions of Cardiovascular Medications and Risk of Acute Coronary Syndrome Recurrence. In GENETIC EPIDEMIOLOGY Vol. 40 (pp. 672). Retrieved from https://www.webofscience.com/
A candidate gene study for oxaliplatin induced chronic peripheral neuropathy (OICPN) based on a prior genome wide association study (GWAS)
Cliff, J. R., Carr, D. F., Lord, R. H., Jorgensen, A. L., & Pirmohamed, M. (2016). A candidate gene study for oxaliplatin induced chronic peripheral neuropathy (OICPN) based on a prior genome wide association study (GWAS). In ANNALS OF ONCOLOGY Vol. 27. doi:10.1093/annonc/mdw392.54
Joint modelling of time-to-event and multivariate longitudinal outcomes: recent developments and issues
Hickey, G. L., Philipson, P., Jorgensen, A., & Kolamunnage-Dona, R. (2016). Joint modelling of time-to-event and multivariate longitudinal outcomes: recent developments and issues. BMC Medical Research Methodology, 16. doi:10.1186/s12874-016-0212-5
Joint models of longitudinal and time-to-event data: extensions and recent developments
Hickey, G. L., Sudell, M., Jorgensen, A., Tudur Smith, C., & Kolamunnage-Dona, R. (2016). Joint models of longitudinal and time-to-event data: extensions and recent developments. Poster session presented at the meeting of ITM Research Day 2016. University of Liverpool.
Joint modelling of longitudinal outcomes and clinical endpoints: JoineR & JoineR-M
Hickey, G. L., Philipson, P., Jorgensen, A., Henderson, R., Diggle, P., Williamson, P., & Kolamunnage-Dona, R. (2016). Joint modelling of longitudinal outcomes and clinical endpoints: JoineR & JoineR-M. Poster session presented at the meeting of MRC Festival of Medical Research. Victoria Gallery and Museum, University of Liverpool.
Evaluation of methodology for the analysis of 'time-to-event' data in pharmacogenomic genome-wide association studies
Syed, H., Jorgensen, A. L., & Morris, A. P. (2016). Evaluation of methodology for the analysis of 'time-to-event' data in pharmacogenomic genome-wide association studies. PHARMACOGENOMICS, 17(8), 907-915. doi:10.2217/pgs.16.19
Adrenal responses to a low-dose short synacthen test in children with asthma (vol 82, pg 648, 2015)
Hawcutt, D. B., Jorgensen, A. L., Wallin, N., Thompson, B., Peak, M., Lacy, D., . . . Smyth, R. L. (2016). Adrenal responses to a low-dose short synacthen test in children with asthma (vol 82, pg 648, 2015). CLINICAL ENDOCRINOLOGY, 84(5), 793. doi:10.1111/cen.13069
A methodological review of joint modelling of multivariate time-to-event data and longitudinal outcomes
Hickey, G. L., Philipson, P., Jorgensen, A., & Kolamunnage-Dona, R. (2016). A methodological review of joint modelling of multivariate time-to-event data and longitudinal outcomes. Poster session presented at the meeting of Joint Modeling and Beyond – Meeting and Tutorial on Joint Modeling With Survival, Longitudinal, and Missing Data. Hasselt University, Belgium.
Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review
Antoniou, M., Jorgensen, A. L., & Kolamunnage-Dona, R. (2016). Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. PLoS One, 11(2). doi:10.1371/journal.pone.0149803
A multi-factorial analysis of response to warfarin in a UK prospective cohort
Bourgeois, S., Jorgensen, A., Zhang, E. J., Hanson, A., Gillman, M. S., Bumpstead, S., . . . Pirmohamed, M. (2016). A multi-factorial analysis of response to warfarin in a UK prospective cohort. Genome Medicine: medicine in the post-genomic era, 8. doi:10.1186/s13073-015-0255-y
A Genome-Wide Two-Component Mixture Model Expectation-Maximisation Algorithm for Time to Event Data
Francis, B., Yin, P., Cook, J. P., Jorgensen, A. L., Hutton, J., & Morris, A. P. (2016). A Genome-Wide Two-Component Mixture Model Expectation-Maximisation Algorithm for Time to Event Data. In HUMAN HEREDITY Vol. 81 (pp. 212-213). Retrieved from https://www.webofscience.com/
A Genome-Wide two-Component Mixture Model Expectation-Maximization Algorithm for Time to Event Data
Francis, B., Yin, P., Cook, J., Jorgensen, A., Hutton, J., & Morris, A. (2016). A Genome-Wide two-Component Mixture Model Expectation-Maximization Algorithm for Time to Event Data. In GENETIC EPIDEMIOLOGY Vol. 40 (pp. 637). Retrieved from https://www.webofscience.com/
SurvivalGWAS_RV: Software to Test Rare Variant Association with "Time-to-Event" Outcomes
Syed, H., Jorgensen, A. L., & Morris, A. P. (2016). SurvivalGWAS_RV: Software to Test Rare Variant Association with "Time-to-Event" Outcomes. In HUMAN HEREDITY Vol. 81 (pp. 230). Retrieved from https://www.webofscience.com/
2015
Circulating Kidney Injury Molecule 1 Predicts Prognosis and Poor Outcome in Patients With Acetaminophen‐Induced Liver Injury
Antoine, D., Sabbisetti, V., Francis, B., Jorgensen, A., Craig, D., Simpson, K., . . . Dear, J. (2015). Circulating Kidney Injury Molecule 1 Predicts Prognosis and Poor Outcome in Patients With Acetaminophen‐Induced Liver Injury. Hepatology, 62(2), 591-599. doi:10.1002/hep.27857
Adrenal responses to a low-dose short synacthen test in children with asthma
Hawcutt, D. B., Jorgensen, A. L., Wallin, N., Thompson, B., Peak, M., Lacy, D., . . . Smyth, R. L. (2015). Adrenal responses to a low-dose short synacthen test in children with asthma. CLINICAL ENDOCRINOLOGY, 82(5), 648-656. doi:10.1111/cen.12655
HLA-allelotype associations with nevirapine-induced hypersensitivity reactions and hepatotoxicity: a systematic review of the literature and meta-analysis.
Cornejo Castro, E. M., Carr, D., Jorgensen, A., Alfirevic, A., & Pirmohamed, M. (2015). HLA-allelotype associations with nevirapine-induced hypersensitivity reactions and hepatotoxicity: a systematic review of the literature and meta-analysis.. Pharmacogenetics and genomics, 25(04), 186-198. doi:10.1097/FPC.0000000000000124
Evaluating statistical characteristics of biomarker-guided trial designs
Antoniou, M., Jorgensen, A., & Kolamunnage-Dona, R. (2015). Evaluating statistical characteristics of biomarker-guided trial designs. TRIALS, 16. doi:10.1186/1745-6215-16-S2-O83
Evaluation of methodology for the analysis of "time-toevent" data in pharmacogenetic studies
Syed, H., Jorgensen, A., & Morris, A. P. (2015). Evaluation of methodology for the analysis of "time-toevent" data in pharmacogenetic studies. In GENETIC EPIDEMIOLOGY Vol. 39 (pp. 584). Retrieved from https://www.webofscience.com/
Genome-Wide Two-Way Competing Risks Approach to Analyse Time to Antiepileptic Drug Withdrawal
Francis, B., Jorgensen, A., Morris, A., Ingason, A., Marson, A., Johnson, M., & Sills, G. (2015). Genome-Wide Two-Way Competing Risks Approach to Analyse Time to Antiepileptic Drug Withdrawal. In HUMAN HEREDITY Vol. 80 (pp. 109-110). Retrieved from https://www.webofscience.com/
Pharmacogenetics of Acute Coronary Syndrome
Yin, P., Jorgensen, A., Morris, A. P., Turner, R., Fitzgerald, R., Stables, R., . . . Pirmohamed, M. (2015). Pharmacogenetics of Acute Coronary Syndrome. In GENETIC EPIDEMIOLOGY Vol. 39 (pp. 596). Retrieved from https://www.webofscience.com/
Powerful Methodology for the Analysis of 'Time-to-Event' Data in Pharmacogenetic Studies
Syed, H., Jorgensen, A., & Morris, A. (2015). Powerful Methodology for the Analysis of 'Time-to-Event' Data in Pharmacogenetic Studies. In HUMAN HEREDITY Vol. 79 (pp. 46-47). Retrieved from https://www.webofscience.com/
The Influence of Pharmacogenetics on the Time to Acute Coronary Syndrome Recurrence in a UK Cohort Study
Yin, P., Jorgensen, A., Morris, A., Turner, R., Fitzgerald, R., Stables, R., . . . Pirmohamed, M. (2015). The Influence of Pharmacogenetics on the Time to Acute Coronary Syndrome Recurrence in a UK Cohort Study. In HUMAN HEREDITY Vol. 80 (pp. 123). Retrieved from https://www.webofscience.com/
Two-Component Mixture Modelling Approach Integrating Genetic and Clinical Variables in Analysis of Time to First Seizure in Epilepsy
Francis, B., Jorgensen, A., Morris, A., Marson, A., Johnson, M., & Sills, G. (2015). Two-Component Mixture Modelling Approach Integrating Genetic and Clinical Variables in Analysis of Time to First Seizure in Epilepsy. In HUMAN HEREDITY Vol. 79 (pp. 34). Retrieved from https://www.webofscience.com/
tSNR as Feature Selection Technique in SNP Data Analysis
Hassan, N., Garcia-Finana, M., Czanner, G., & Jorgensen, A. (2015). tSNR as Feature Selection Technique in SNP Data Analysis. In HUMAN HEREDITY Vol. 80 (pp. 112). Retrieved from https://www.webofscience.com/
2014
A Review of A Priori Regression Models for Warfarin Maintenance Dose Prediction
Francis, B., Lane, S., Pirmohamed, M., & Jorgensen, A. (2014). A Review of A Priori Regression Models for Warfarin Maintenance Dose Prediction. PLoS One, 9(12). doi:10.1371/journal.pone.0114896
Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects.
Hawcutt, D., Ghani, A., Sutton, L., Jorgensen, A., Zhang, E., Murray, M., . . . Pirmohamed, M. (2014). Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects.. The Pharmacogenomics Journal, 14(6), 542-548. doi:10.1038/tpj.2014.31
CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations
Carr, D. F., Chaponda, M., Cornejo Castro, E. M., Jorgensen, A. L., Khoo, S., Van Oosterhout, J. J., . . . Pirmohamed, M. (2014). CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations. Journal of Antimicrobial Chemotherapy, 69(12), 3329-3334. doi:10.1093/jac/dku315
Reference intervals for urinary renal injury biomarkers KIM-1 and NGAL in healthy children
McWilliam, S. J., Antoine, D. J., Sabbisetti, V. S., Pearce, R. E., Jorgensen, A. L., Lin, Y., . . . Pirmohamed, M. (2014). Reference intervals for urinary renal injury biomarkers KIM-1 and NGAL in healthy children. Biomarkers in Medicine, 8(10), 1189-1197. doi:10.2217/bmm.14.36
WHICH GENETIC PATHWAYS UNDERLIE PHARMACORESISTANT EPILEPSY?
Mirza, N., Jorgensen, A., Sills, G., Johnson, M., Pirmohamed, M., & Marson, T. (2014). WHICH GENETIC PATHWAYS UNDERLIE PHARMACORESISTANT EPILEPSY?. In JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY Vol. 85. doi:10.1136/jnnp-2014-309236.6
Cervical stitch (cerclage) for preventing preterm birth in multiple pregnancy
Alfirevic, Z., Rafael, T. J., & Berghella, V. (2014). Cervical stitch (cerclage) for preventing preterm birth in multiple pregnancy. Cochrane Database of Systematic Reviews, 2014(9), 1-55. doi:10.1002/14651858.CD009166.pub2
Folate Augmentation of Treatment--Evaluation for Depression (FolATED): randomised trial and economic evaluation.
Bedson, E., Bell, D., Carr, D., Carter, B., Hughes, D., Jorgensen, A., . . . Williams, N. (2014). Folate Augmentation of Treatment--Evaluation for Depression (FolATED): randomised trial and economic evaluation.. Health Technology Assessment, 18(48). doi:10.3310/hta18480
CYP2B6*18 is associated with nevirpine hypersensitivity independently of HLA-C*04:01 in a Malawian HIV population
Carr, D., Chaponda, M., Castro, E. C., Jorgensen, A., Khoo, S., & Pirmohamed, M. (2014). CYP2B6*18 is associated with nevirpine hypersensitivity independently of HLA-C*04:01 in a Malawian HIV population. Clinical and translational allergy, 4(Suppl 3), P126. doi:10.1186/2045-7022-4-s3-p126
A genome-wide association study and biological pathway analysis of epilepsy prognosis in a prospective cohort of newly treated epilepsy
Speed, D., Hoggart, C., Petrovski, S., Tachmazidou, I., Coffey, A., Jorgensen, A., . . . Johnson, M. R. (2014). A genome-wide association study and biological pathway analysis of epilepsy prognosis in a prospective cohort of newly treated epilepsy. Human Molecular Genetics, 23(1), 247-258. doi:10.1093/hmg/ddt403
IDENTIFYING THE CAUSES OF PHARMACORESISTANT EPILEPSY THROUGH A GENOME-WIDE ASSOCIATION STUDY WITH PATHWAY AND NETWORK ANALYSIS: FROM COMPLEXITY TO COHERENCE TO CENTRALITY
Mirza, N., Jorgensen, A., Sills, G., Johnson, M., Pirmohamed, M., & Marson, A. G. (2014). IDENTIFYING THE CAUSES OF PHARMACORESISTANT EPILEPSY THROUGH A GENOME-WIDE ASSOCIATION STUDY WITH PATHWAY AND NETWORK ANALYSIS: FROM COMPLEXITY TO COHERENCE TO CENTRALITY. In EPILEPSIA Vol. 55 (pp. 10). Retrieved from https://www.webofscience.com/
Identifying the causes of pharmacoresistant epilepsy through a genome-wide association study with pathway and network analysis: from complexity to coherence to centrality
Mirza, N., Sills, G., Jorgensen, A., Johnson, M., Pirmohamed, M., & Marson, A. G. (2014). Identifying the causes of pharmacoresistant epilepsy through a genome-wide association study with pathway and network analysis: from complexity to coherence to centrality. In JOURNAL OF NEUROLOGY Vol. 261 (pp. S484-S485). Retrieved from https://www.webofscience.com/
Identifying the causes of pharmacoresistant epilepsy through a genome-wide association study with pathway and network analysis: from complexity to coherence to centrality
Mirza, N., Sills, G., Jorgensen, A., Johnson, M., Pirmohamed, M., & Marson, A. G. (2014). Identifying the causes of pharmacoresistant epilepsy through a genome-wide association study with pathway and network analysis: from complexity to coherence to centrality. In EUROPEAN JOURNAL OF NEUROLOGY Vol. 21 (pp. 755). Retrieved from https://www.webofscience.com/
Reference intervals for urinary renal injury biomarkers KIM-1 and NGAL in healthy children
McWilliam, S. J., Antoine, D. J., Sabbisetti, V., Pearce, R. E., Jorgensen, A. L., Lin, Y., . . . Pirmohamed, M. (2014). Reference intervals for urinary renal injury biomarkers KIM-1 and NGAL in healthy children. Biomarker Medicine.
2013
Genetic testing for prevention of severe drug-induced skin rash
Alfirevic, A., Pirmohamed, M., Marinovic, B., Jorgensen, A. L., & Harcourt-Smith, L. (n.d.). Genetic testing for prevention of severe drug-induced skin rash. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd010891
A Randomized Trial of Genotype-Guided Dosing of Warfarin
Pirmohamed, M., Burnside, G., Eriksson, N., Jorgensen, A. L., Toh, C. H., Nicholson, T., . . . Wadelius, M. (2013). A Randomized Trial of Genotype-Guided Dosing of Warfarin. New England Journal of Medicine, 369(24), 2294-2303. doi:10.1056/nejmoa1311386
A Randomized Trial of Genotype-Guided Dosing of Warfarin
Pirmohamed, M., Burnside, G., Eriksson, N., Jorgensen, A. L., Toh, C. H., Nicholson, T., . . . Wadelius, M. (2013). A Randomized Trial of Genotype-Guided Dosing of Warfarin. NEW ENGLAND JOURNAL OF MEDICINE, 369(24), 2294-2303. doi:10.1056/NEJMoa1311386
<i>SLCO1B1</i> Genetic Variant Associated With Statin-Induced Myopathy: A Proof-of-Concept Study Using the Clinical Practice Research Datalink
Carr, D. F., O'Meara, H., Jorgensen, A. L., Campbell, J., Hobbs, M., McCann, G., . . . Pirmohamed, M. (2013). <i>SLCO1B1</i> Genetic Variant Associated With Statin-Induced Myopathy: A Proof-of-Concept Study Using the Clinical Practice Research Datalink. CLINICAL PHARMACOLOGY & THERAPEUTICS, 94(6), 695-701. doi:10.1038/clpt.2013.161
Association of Human Leukocyte Antigen Alleles and Nevirapine Hypersensitivity in a Malawian HIV-Infected Population
Carr, D. F., Chaponda, M., Jorgensen, A. L., Castro, E. C., van Oosterhout, J. J., Khoo, S. H., . . . Pirmohamed, M. (2013). Association of Human Leukocyte Antigen Alleles and Nevirapine Hypersensitivity in a Malawian HIV-Infected Population. CLINICAL INFECTIOUS DISEASES, 56(9), 1330-1339. doi:10.1093/cid/cit021
<i>CYP2C19*17</i> Gain-of-Function Polymorphism Is Associated With Peptic Ulcer Disease
Musumba, C. O., Jorgensen, A., Sutton, L., Van Eker, D., Zhang, E., O'Hara, N., . . . Pirmohamed, M. (2013). <i>CYP2C19*17</i> Gain-of-Function Polymorphism Is Associated With Peptic Ulcer Disease. CLINICAL PHARMACOLOGY & THERAPEUTICS, 93(2), 195-203. doi:10.1038/clpt.2012.215
The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia
Giannoudis, A., Wang, L., Jorgensen, A. L., Xinarianos, G., Davies, A., Pushpakom, S., . . . Clark, R. E. (2013). The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. BLOOD, 121(4), 628-637. doi:10.1182/blood-2012-01-405035
A Randomized Trial Comparing Genotype-Guided Dosing of Warfarin to Standard Dosing: The EU Pharmacogenetics of Anticoagulant Therapy (EU-PACT) Warfarin Study
Pirmohamed, M., Burnside, G., Stoddern, J., Prince, C., Toh, C. H., Nicholson, T., . . . Wadelius, M. (2013). A Randomized Trial Comparing Genotype-Guided Dosing of Warfarin to Standard Dosing: The EU Pharmacogenetics of Anticoagulant Therapy (EU-PACT) Warfarin Study. CIRCULATION, 128(24), 2710-2711. Retrieved from https://www.webofscience.com/
A Randomized Trial of Genotype-Guided Dosing of Warfarin
Pirmohamed, M., Burnside, G., Eriksson, N., Jorgensen, A. L., Toh, C. H., Nicholson, T., & al., E. (2013). A Randomized Trial of Genotype-Guided Dosing of Warfarin. New England Journal of Medicine, (369), 2294-2303.
A genome-wide association study and biological pathway analysis of epilepsy prognosis in a prospective cohort of newly treated epilepsy.
Speed, D., Hoggart, C., Petrovski, S., Tachmazidou, I., Coffey, A., Jorgensen, A., . . . Johnson, M. R. (2013). A genome-wide association study and biological pathway analysis of epilepsy prognosis in a prospective cohort of newly treated epilepsy.. Human Molecular Genetics.
Adherence and variability in warfarin dose requirements: assessment in a prospective cohort
Jorgensen, A. L., Hughes, D. A., Hanson, A., van Eker, D., Toh, C. H., Pirmohamed, M., & Williamson, P. R. (2013). Adherence and variability in warfarin dose requirements: assessment in a prospective cohort. PHARMACOGENOMICS, 14(2), 151-163. doi:10.2217/PGS.12.199
Adherence and variability in warfarin dose requirements: assessment in a prospective cohort.
Jorgensen, A. L., Hughes, D. A., Hanson, A., van Eker, D., Toh, C. H., Pirmohamed, M., & Williamson, P. R. (2013). Adherence and variability in warfarin dose requirements: assessment in a prospective cohort..
Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population.
Carr, D. F., Chaponda, M., Jorgensen, A. L., Castro, E. C., van Oosterhout, J. J., Khoo, S. H., . . . Pirmohamed, M. (2013). Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population..
Institutional profile: the Wolfson Centre for Personalised Medicine, University of Liverpool, Liverpool, UK.
Alfirevic, A., Carr, D. F., Miyajima, F., Pushpakom, S., Sutton, L., Jorgensen, A. L., & Pirmohamed, M. (2013). Institutional profile: the Wolfson Centre for Personalised Medicine, University of Liverpool, Liverpool, UK..
SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink
Carr, D. F., O'Meara, H., Jorgensen, A. L., Campbell, J., Hobbs, M., McCann, G., . . . Pirmohamed, M. (2013). SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clinical Pharmacology and Therapeutics, 94(6), 695-701. doi:10.1038/clpt.2013
Systematic review of pharmacogenomics in psoriasis
Foulkes, A. C., Jorgensen, A., Pirmohamed, M., Griffiths, C. E., & Warren, R. B. (2013). Systematic review of pharmacogenomics in psoriasis. In JOURNAL OF INVESTIGATIVE DERMATOLOGY Vol. 133 (pp. S88). Retrieved from https://www.webofscience.com/
The Wolfson Centre for Personalised Medicine, University of Liverpool, Liverpool, UK
Alfirevic, A., Carr, D. F., Miyajima, F., Pushpakom, S., Sutton, L., Jorgensen, A. L., & Pirmohamed, M. (2013). The Wolfson Centre for Personalised Medicine, University of Liverpool, Liverpool, UK. PHARMACOGENOMICS, 14(8), 861-867. doi:10.2217/PGS.13.73
The hOCT1 single nucleotide polymorphisms M420del and M408V alter imatinib uptake and modify clinical outcome in imatinib treated chronic myeloid leukaemia
Giannoudis, A., Wang, L., Jorgensen, A. L., Xinarianos, G., Davies, A., Pushpakom, S., . . . Clark, R. E. (2013). The hOCT1 single nucleotide polymorphisms M420del and M408V alter imatinib uptake and modify clinical outcome in imatinib treated chronic myeloid leukaemia. Blood, 121, 628-637.
2012
HLA Genotype and Carbamazepine-Induced Cutaneous Adverse Drug Reactions: A Systematic Review
Yip, V. L., Marson, A. G., Jorgensen, A. L., Pirmohamed, M., & Alfirevic, A. (2012). HLA Genotype and Carbamazepine-Induced Cutaneous Adverse Drug Reactions: A Systematic Review. CLINICAL PHARMACOLOGY & THERAPEUTICS, 92(6), 757-765. doi:10.1038/clpt.2012.189
HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review.
Yip, V., Marson, T., Jorgensen, A., Pirmohamed, M., & Alfirevic, A. (2012). HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review.. Clinical Pharmacology and Therapeutics, 92(6), 757-765.
VARIATION AT GLCCI1: ASSOCIATION WITH INCREASED STEROID DOSE BUT NOT ADRENAL SUPPRESSION IN ASTHMATIC CHILDREN
Thompson, B., Hawcutt, D. B., Carr, D. F., Jorgensen, A. L., Smyth, R. L., & Pirmohamed, M. (2012). VARIATION AT GLCCI1: ASSOCIATION WITH INCREASED STEROID DOSE BUT NOT ADRENAL SUPPRESSION IN ASTHMATIC CHILDREN. THORAX, 67, A17. doi:10.1136/thoraxjnl-2012-202678.037
Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-Analysis
Jorgensen, A. L., FitzGerald, R. J., Oyee, J., Pirmohamed, M., & Williamson, P. R. (2012). Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-Analysis. PLOS ONE, 7(8). doi:10.1371/journal.pone.0044064
CYP2C19*17 GAIN OF FUNCTION MUTATION IS ASSOCIATED WITH PEPTIC ULCER DISEASE
Musumba, C. O., Eker, D. V., Jorgensen, A., Pritchard, D. M., & Pirmohamed, M. (2012). CYP2C19*17 GAIN OF FUNCTION MUTATION IS ASSOCIATED WITH PEPTIC ULCER DISEASE. GUT, 61, A363. doi:10.1136/gutjnl-2012-302514d.165
Su1780 CYP2C19*17 Gain of Function Mutation is Associated With the Development of Peptic Ulcer Disease
Musumba, C. O., Van Eker, D., Jorgensen, A. L., Zhang, E., O'Hara, N., Pritchard, M., & Pirmohamed, M. (2012). Su1780 CYP2C19*17 Gain of Function Mutation is Associated With the Development of Peptic Ulcer Disease. Gastroenterology, 142(5), S-502. doi:10.1016/s0016-5085(12)61922-2
Cervical stitch (cerclage) for preventing preterm birth in singleton pregnancy
Alfirevic, Z., Stampalija, T., Roberts, D., & Jorgensen, A. L. (2012). Cervical stitch (cerclage) for preventing preterm birth in singleton pregnancy. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (4). doi:10.1002/14651858.CD008991.pub2
Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy
Horne, B. D., Lenzini, P. A., Wadelius, M., Jorgensen, A. L., Kimmel, S. E., Ridker, P. M., . . . Gage, B. F. (2012). Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. THROMBOSIS AND HAEMOSTASIS, 107(2), 232-240. doi:10.1160/TH11-06-0388
CYP2C19*17 Gain of Function Mutation is Associated With the Development of Peptic Ulcer Disease
Musumba, C. O., Van Eker, D., Jorgensen, A. L., Zhang, E., O'Hara, N., Pritchard, M., & Pirmohamed, M. (2012). CYP2C19*17 Gain of Function Mutation is Associated With the Development of Peptic Ulcer Disease. In GASTROENTEROLOGY Vol. 142 (pp. S502). Retrieved from https://www.webofscience.com/
HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review
Yip, V. L., Marson, A. G., Jorgensen, A. L., Pirmohamed, M., & Alfirevic, A. (2012). HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clinical Pharmacology and Therapeutics, 92(6), 757-765.
The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors
Lane, S., Al-Zubiedi, S., Hatch, E., Matthews, I., Jorgensen, A. L., Deloukas, P., . . . Pirmohamed, M. (2012). The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. British Journal of Clinical Pharmacology.
The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors
Lane, S., Al-Zubiedi, S., Hatch, E., Matthews, I., Jorgensen, A. L., Deloukas, P., . . . Pirmohamed, M. (2012). The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 73(1), 66-76. doi:10.1111/j.1365-2125.2011.04051.x
The relative contribution of NSAIDs and Helicobacter pylori to the aetiology of endoscopically-diagnosed peptic ulcer disease: observations from a tertiary referral hosiptal in the UK between 2005 and 2010
Musumba, C., Jorgensen, A., Sutton, L., Van Eker, D., Moorcroft, J., Hopkins, M., . . . Pirmohamed, M. (2012). The relative contribution of NSAIDs and Helicobacter pylori to the aetiology of endoscopically-diagnosed peptic ulcer disease: observations from a tertiary referral hosiptal in the UK between 2005 and 2010. Alimentary Pharmacology and Therapeutics, 36(1), 48-56.
The relative contribution of NSAIDs and Helicobacter pylori to the aetiology of endoscopically-diagnosed peptic ulcer disease: observations from a tertiary referral hospital in the UK between 2005 and 2010
Musumba, C., Jorgensen, A., Sutton, L., Van Eker, D., Moorcroft, J., Hopkins, M., . . . Pirmohamed, M. (2012). The relative contribution of NSAIDs and Helicobacter pylori to the aetiology of endoscopically-diagnosed peptic ulcer disease: observations from a tertiary referral hospital in the UK between 2005 and 2010. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 36(1), 48-56. doi:10.1111/j.1365-2036.2012.05118.x
2011
A Proposal for an Individualized Pharmacogenetics-Based Warfarin Initiation Dose Regimen for Patients Commencing Anticoagulation Therapy
Avery, P. J., Jorgensen, A., Hamberg, A., Wadelius, M., Pirmohamed, M., & Kamali, F. (2011). A Proposal for an Individualized Pharmacogenetics-Based Warfarin Initiation Dose Regimen for Patients Commencing Anticoagulation Therapy. CLINICAL PHARMACOLOGY & THERAPEUTICS, 90(5), 701-706. doi:10.1038/clpt.2011.186
Changing Trends in Peptic Ulcer Disease: The Rise of NSAID-Induced and Fall of Helicobacter pylori -Induced Ulcers
Musumba, C. O., Van Eker, D., Jorgensen, A., Pritchard, M., & Pirmohamed, M. (2011). Changing Trends in Peptic Ulcer Disease: The Rise of NSAID-Induced and Fall of Helicobacter pylori -Induced Ulcers. Gastroenterology, 140(5), S-176. doi:10.1016/s0016-5085(11)60711-7
CHANGING TRENDS IN PEPTIC ULCER DISEASE: THE RISE OF NSAID-INDUCED AND FALL OF <i>H PYLORI</i>-INDUCED ULCERS
Musumba, C. O., Van Eker, D., Jorgensen, A., Pritchard, M., & Pirmohamed, M. (2011). CHANGING TRENDS IN PEPTIC ULCER DISEASE: THE RISE OF NSAID-INDUCED AND FALL OF <i>H PYLORI</i>-INDUCED ULCERS. In GUT Vol. 60. doi:10.1136/gut.2011.239301.219
Risk modeling strategies for pharmacogenetic studies
Jorgensen, A. L., & Pirmohamed, M. (2011). Risk modeling strategies for pharmacogenetic studies. PHARMACOGENOMICS, 12(3), 397-410. doi:10.2217/PGS.10.198
Cervical stitch (cerclage) for preventing preterm birth in singleton pregnancy
Alfirevic, Z., Stampalija, T., Roberts, D., & Jorgensen, A. L. (n.d.). Cervical stitch (cerclage) for preventing preterm birth in singleton pregnancy. In Z. Alfirevic (Ed.). John Wiley & Sons, Ltd. doi:10.1002/14651858.cd008991
Changing Trends in Peptic Ulcer Disease: The Rise of NSAID-Induced and Fall of <i>Helicobacter pylori</i>-Induced Ulcers
Musumba, C. O., Van Eker, D., Jorgensen, A., Pritchard, M., & Pirmoltamed, M. (2011). Changing Trends in Peptic Ulcer Disease: The Rise of NSAID-Induced and Fall of <i>Helicobacter pylori</i>-Induced Ulcers. In GASTROENTEROLOGY Vol. 140 (pp. S176). Retrieved from https://www.webofscience.com/
Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses
Fleeman, N., Dundar, Y., Dickson, R., Jorgensen, A., Pushpakom, S., McLeod, C., . . . Walley, T. (2011). Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. PHARMACOGENOMICS JOURNAL, 11(1), 1-14. doi:10.1038/tpj.2010.73
Metabolic acidosis with topiramate and zonisamide: an assessment of its severity and predictors
Mirza, N. S., Alfirevic, A., Jorgensen, A., Marson, A. G., & Pirmohamed, M. (2011). Metabolic acidosis with topiramate and zonisamide: an assessment of its severity and predictors. PHARMACOGENETICS AND GENOMICS, 21(5), 297-302. doi:10.1097/FPC.0b013e3283441b95
2010
Warfarin pharmacogenetics: a single <i>VKORC1</i> polymorphism is predictive of dose across 3 racial groups
Limdi, N. A., Wadelius, M., Cavallari, L., Eriksson, N., Crawford, D. C., Lee, M. -T. M., . . . Wagner, M. J. (2010). Warfarin pharmacogenetics: a single <i>VKORC1</i> polymorphism is predictive of dose across 3 racial groups. BLOOD, 115(18), 3827-3834. doi:10.1182/blood-2009-12-255992
Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing
Lenzini, P., Wadelius, M., Kimmel, S., Anderson, J. L., Jorgensen, A. L., Pirmohamed, M., . . . Gage, B. F. (2010). Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing. CLINICAL PHARMACOLOGY & THERAPEUTICS, 87(5), 572-578. doi:10.1038/clpt.2010.13
WARFARIN DOSING ALGORITHM REFINEMENTS AFTER 7-9 DAYS OF THERAPY BASED ON PHARMACOGENETIC, PHARMACOKINETIC, CLINICAL, AND LABORATORY DATA
Horne, B. D., Lenzini, P. A., Wadelius, M., Jorgensen, A. L., Kimmel, S. E., Eriksson, N., . . . Gage, B. F. (2010). WARFARIN DOSING ALGORITHM REFINEMENTS AFTER 7-9 DAYS OF THERAPY BASED ON PHARMACOGENETIC, PHARMACOKINETIC, CLINICAL, AND LABORATORY DATA. Journal of the American College of Cardiology, 55(10), A130.E1218. doi:10.1016/s0735-1097(10)61219-3
CYP4F2 genotype-phenotype correlation in human liver
Zhang, J. E., Jorgensen, A., Kline, K., Alfirevic, A., Zanger, U., & Pirmohamed, M. (2010). CYP4F2 genotype-phenotype correlation in human liver. In BRITISH JOURNAL OF CLINICAL PHARMACOLOGY Vol. 70 (pp. 297-298). Retrieved from https://www.webofscience.com/
Carbamazepine-induced hypersensitivity in Caucasians and genetic variability in the major histocompatibility complex
Alfirevic, A., Bourgeois, S., Jorgensen, A., Steen, K., Weetman, D., Park, B. K., . . . Pirmohamed, M. (2010). Carbamazepine-induced hypersensitivity in Caucasians and genetic variability in the major histocompatibility complex. In BRITISH JOURNAL OF CLINICAL PHARMACOLOGY Vol. 70 (pp. 298). Retrieved from https://www.webofscience.com/
Improving the evidence base in pharmacogenetic studies: warfarin as an example
Jorgensen, A. L. (2010). Improving the evidence base in pharmacogenetic studies: warfarin as an example. (PhD Thesis, University of Liverpool).
Integration of genetic, clinical, and INR data to refine warfarin dosing
Lenzini, P., Wadelius, M., Kimmel, S., Anderson, J. L., Jorgensen, A. L., Pirmohamed, M., & al., E. (2010). Integration of genetic, clinical, and INR data to refine warfarin dosing. Unknown Journal, 87(5), 572-578.
Metabolic acidosis with topiramate and zonisamide: an assessment of its severity and predictors.
Mirza, N. S., Alfirevic, A., Jorgensen, A., Marson, A. G., & Pirmohamed, M. (2010). Metabolic acidosis with topiramate and zonisamide: an assessment of its severity and predictors.. Pharmacogenetics and Genomics, 21(5), 297-302.
Proposal of a pharmacogenetic-based dosing algorithm for the induction of warfarin anticoagulation therapy in patients with thromboembolic disease
Avery, P., Pirmohamed, M., Jorgensen, A., & Kamali, F. (2010). Proposal of a pharmacogenetic-based dosing algorithm for the induction of warfarin anticoagulation therapy in patients with thromboembolic disease. In BRITISH JOURNAL OF CLINICAL PHARMACOLOGY Vol. 70 (pp. 291). Retrieved from https://www.webofscience.com/
The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation
Fleeman, N., McLeod, C., Bagust, A., Beale, S., Boland, A., Dundar, Y., . . . Dickson, R. (2010). The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 14(3), 1-+. doi:10.3310/hta14030
2009
Effects of <i>CYP4F2</i> genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy
Zhang, J. E., Jorgensen, A. L., Alfirevic, A., Williamson, P. R., Toh, C. H., Park, B. K., & Pirmohamed, M. (2009). Effects of <i>CYP4F2</i> genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy. PHARMACOGENETICS AND GENOMICS, 19(10), 781-789. doi:10.1097/FPC.0b013e3283311347
Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study
Jorgensen, A. L., Al-Zubiedi, S., Zhang, J. E., Keniry, A., Hanson, A., Hughes, D. A., . . . Pirmohamed, M. (2009). Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. PHARMACOGENETICS AND GENOMICS, 19(10), 800-812. doi:10.1097/FPC.0b013e3283317ab5
IMPACT OF PHARMACOGENETICS ON THE COSTS OF MANAGING ADVERSE EVENTS WITH WARFARIN: A PROSPECTIVE ANALYSIS
Hughes, D. A., Al-Zubiedi, S., Hanson, A., Jorgensen, A., & Pirmohamed, M. (2009). IMPACT OF PHARMACOGENETICS ON THE COSTS OF MANAGING ADVERSE EVENTS WITH WARFARIN: A PROSPECTIVE ANALYSIS. VALUE IN HEALTH, 12(3), A3-A4. doi:10.1016/S1098-3015(10)73081-3
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
Klein, T. E., Altman, R. B., Eriksson, N., Gage, B. F., Kimmel, S. E., Lee, M. -T. M., . . . Shin, J. G. (2009). Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data. NEW ENGLAND JOURNAL OF MEDICINE, 360(8), 753-764. Retrieved from https://www.webofscience.com/
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data (vol 360, pg 753, 2009)
Klein, T. E., Altman, R. B., Eriksson, N., Gage, B. F., Kimmel, S. E., Lee, M. T. M., . . . Shin, J. G. (2009). Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data (vol 360, pg 753, 2009). NEW ENGLAND JOURNAL OF MEDICINE, 361(16), 1613. Retrieved from https://www.webofscience.com/
Systematic Review of Pharmacogenetic Warfarin Dosing
van Schie, R. M. F., Jorgensen, A. L., de Boer, A., & Maitland-van der Zee, A. -H. (2009). Systematic Review of Pharmacogenetic Warfarin Dosing. JOURNAL OF GENERAL INTERNAL MEDICINE, 24(10), 1171. doi:10.1007/s11606-009-1083-9
2008
Methodological quality of pharmacogenetic studies: Issues of concern
Jorgensen, A. L., & Williamson, P. R. (2008). Methodological quality of pharmacogenetic studies: Issues of concern. STATISTICS IN MEDICINE, 27(30), 6547-6569. doi:10.1002/sim.3420
Pharmacogenetics and pharmacogenomics: adverse drug reactions.
Jorgensen, A., & Alfirevic, A. (2008). Pharmacogenetics and pharmacogenomics: adverse drug reactions.. Pharmacogenomics, 9(10), 1397-1401. doi:10.2217/14622416.9.10.1397
Cervical Stitch (Cerclage) For Preventing Pregnancy Loss: Individual Patient Data Meta-Analysis
Jorgensen, A. L., Alfirevic, Z., Tudur Smith, C., & Williamson, P. R. (2008). Cervical Stitch (Cerclage) For Preventing Pregnancy Loss: Individual Patient Data Meta-Analysis. Obstetric Anesthesia Digest, 28(3), 149-150. doi:10.1097/01.aoa.0000326390.19993.0d
A randomized controlled clinical trial of 2295 ultrasound-guided embryo transfers
Drakeley, A. J., Jorgensen, A., Sklavounos, J., Aust, T., Gazvani, R., Williamson, P., & Kingsland, C. R. (2008). A randomized controlled clinical trial of 2295 ultrasound-guided embryo transfers. HUMAN REPRODUCTION, 23(5), 1101-1106. doi:10.1093/humrep/den064
Cervical stitch (cerclage) for preventing pregnancy loss: individual patient data meta-analysis - Author's reply
Jorgensen, A. L., Alfirevic, Z., Smith, C. T., & Williamson, P. R. (2008). Cervical stitch (cerclage) for preventing pregnancy loss: individual patient data meta-analysis - Author's reply. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 115(6), 798-799. doi:10.1111/j.1471-0528.2008.01689.x
Cervical Stitch (Cerclage) for Preventing Pregnancy Loss: Individual Patient Data Meta-Analysis
Jorgensen, A. L., Alfirevic, Z., Smith, C. T., & Williamson, P. R. (2008). Cervical Stitch (Cerclage) for Preventing Pregnancy Loss: Individual Patient Data Meta-Analysis. Obstetrical & Gynecological Survey, 63(3), 135-136. doi:10.1097/01.ogx.0000305196.42050.6e
Warfarin pharmacogenetics: ready for clinical implementation?
Jorgensen, A. L. (2008). Warfarin pharmacogenetics: ready for clinical implementation?. JOURNAL OF PHARMACY AND PHARMACOLOGY, 60, A66-A67. Retrieved from https://www.webofscience.com/
2007
Cervical stitch (cerclage) for preventing pregnancy loss: Individual patient data meta-analysis
Jorgensen, A. L., Alfirevic, Z., Smith, C. T., & Williamson, P. R. (2007). Cervical stitch (cerclage) for preventing pregnancy loss: Individual patient data meta-analysis. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 114(12), 1460-1476. doi:10.1111/j.1471-0528.2007.01515.x
The association between polymorphisms in <i>RLIP76</i> and drug response in epilepsy
Leschziner, G. D., Jorgensen, A. L., Andrews, T., Williamson, P. R., Marson, A. G., Coffey, A. J., . . . Pirmohamed, M. (2007). The association between polymorphisms in <i>RLIP76</i> and drug response in epilepsy. PHARMACOGENOMICS, 8(12), 1715-1722. doi:10.2217/14622416.8.12.1715
2006
<i>HLA-B</i> locus in Caucasian patients with carbamazepine hypersensitivity
Alfirevic, A., Jorgensen, A. L., Williamson, P. R., Chadwick, D. W., Park, B. K., & Pirmohamed, M. (2006). <i>HLA-B</i> locus in Caucasian patients with carbamazepine hypersensitivity. PHARMACOGENOMICS, 7(6), 813-818. doi:10.2217/14622416.7.6.813
Clinical factors and <i>ABCB1</i> polymorphisms in prediction of antiepileptic drug response:: a prospective cohort study
Leschziner, G., Jorgensen, A. L., Andrew, T., Pirmohaomed, M., Williamson, P. R., Marson, A. G., . . . Johnson, M. R. (2006). Clinical factors and <i>ABCB1</i> polymorphisms in prediction of antiepileptic drug response:: a prospective cohort study. LANCET NEUROLOGY, 5(8), 668-676. doi:10.1016/S1474-4422(06)70500-2
ABCB1 polymorphisms and haplotype previously associated with drug resistant epilepsy have no effect on therapeutic or adverse drug response in a large prospective epilepsy cohort
Leschziner, G., Jorgensen, A., Andrew, T., Middleditch, C., Pirmohamed, M., Williamson, P., . . . Johnson, M. R. (2006). ABCB1 polymorphisms and haplotype previously associated with drug resistant epilepsy have no effect on therapeutic or adverse drug response in a large prospective epilepsy cohort. In JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY Vol. 77 (pp. 1394). Retrieved from https://www.webofscience.com/
ACB1 polymorphisms and haplotype previously associated with drug-resistant epilepsy have no effect on therapeutic or adverse drug response in a large prospective cohort
Leschziner, G. D., Jorgensen, A., Andrew, T., Middleditch, C., Pirmohamed, M., Marson, T., . . . Johnson, M. R. (2006). ACB1 polymorphisms and haplotype previously associated with drug-resistant epilepsy have no effect on therapeutic or adverse drug response in a large prospective cohort. In DRUG METABOLISM REVIEWS Vol. 38 (pp. 84). Retrieved from https://www.webofscience.com/
2005
Individual patient data meta-analysis : Cervical stitch (cerclage) for preventing pregnancy loss in women.
Tudur-Smith, C., Jorgensen, A. L., Alfirevic, Z., & Williamson, P. R. (2005). Individual patient data meta-analysis : Cervical stitch (cerclage) for preventing pregnancy loss in women.. BMC pregnancy and childbirth, 5(1), 5. doi:10.1186/1471-2393-5-5